| Name | (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[5-methyl-1-propan-2-yl-4-[(4-propan-2-yloxyphenyl)methyl]pyrazol-3-yl]oxyoxane-3,4,5-triol |
|---|---|
| Synonyms |
Remogliflozin A
UNII-13ZPK7A4MJ [14C]-Remogliflozin |
| Description | Remogliflozin is a potent and selective inhibitor of SGLT2 (sodium-glucose cotransporter 2) with Kis of 12.4 and 26 nM for human and rat SGLT2, respectively[1]. |
|---|---|
| Related Catalog | |
| References |
| Molecular Formula | C23H34N2O7 |
|---|---|
| Molecular Weight | 450.53 |
| Exact Mass | 450.23700 |
| PSA | 126.43000 |
| LogP | 1.32910 |
|
~%
329045-45-6 |
| Literature: GLAXOSMITHKLINE LLC; MARTIN, Michael Tolar; MCCLURE, Michael S; ELITZIN, Vassil Patent: WO2010/59774 A1, 2010 ; Location in patent: Page/Page column 26-27 ; WO 2010/059774 A1 |